Oncopeptides AB Performance
| ONPPFDelisted Stock | USD 0.27 0.00 0.00% |
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Oncopeptides are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Oncopeptides is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 840.3 M | |
| Total Cashflows From Investing Activities | -339 K |
Oncopeptides |
Oncopeptides Relative Risk vs. Return Landscape
If you would invest 27.00 in Oncopeptides AB on October 1, 2025 and sell it today you would earn a total of 0.00 from holding Oncopeptides AB or generate 0.0% return on investment over 90 days. Oncopeptides AB is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Oncopeptides, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Oncopeptides Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncopeptides' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Oncopeptides AB, and traders can use it to determine the average amount a Oncopeptides' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ONPPF |
Based on monthly moving average Oncopeptides is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncopeptides by adding Oncopeptides to a well-diversified portfolio.
Oncopeptides Fundamentals Growth
Oncopeptides Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Oncopeptides, and Oncopeptides fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncopeptides Pink Sheet performance.
| Return On Equity | -1.29 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 75.14 M | |||
| Shares Outstanding | 90.37 M | |||
| Price To Book | 14.19 X | |||
| Price To Sales | 17.15 X | |||
| Revenue | 118.3 M | |||
| EBITDA | (1.41 B) | |||
| Debt To Equity | 0.05 % | |||
| Cash Flow From Operations | (1.52 B) | |||
| Total Asset | 439.38 M | |||
About Oncopeptides Performance
By analyzing Oncopeptides' fundamental ratios, stakeholders can gain valuable insights into Oncopeptides' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncopeptides has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncopeptides has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Oncopeptides AB , a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Oncopeptides AB was incorporated in 2000 and is headquartered in Stockholm, Sweden. Oncopeptides is traded on OTC Exchange in the United States.Things to note about Oncopeptides AB performance evaluation
Checking the ongoing alerts about Oncopeptides for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Oncopeptides AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncopeptides AB is not yet fully synchronised with the market data | |
| Oncopeptides AB has some characteristics of a very speculative penny stock | |
| Oncopeptides AB has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 118.3 M. Net Loss for the year was (1.43 B) with profit before overhead, payroll, taxes, and interest of 74.16 M. | |
| Oncopeptides generates negative cash flow from operations |
- Analyzing Oncopeptides' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncopeptides' stock is overvalued or undervalued compared to its peers.
- Examining Oncopeptides' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncopeptides' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncopeptides' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncopeptides' pink sheet. These opinions can provide insight into Oncopeptides' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Oncopeptides Pink Sheet
If you are still planning to invest in Oncopeptides AB check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncopeptides' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |